SCHEMBL7629504

SCHEMBL7629504

CCOC(=O)[C@H](O)CC(=O)c1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.73
NPC1 O15118 3/20 0.73
MEN1 O00255 3/20 0.73
POLB P06746 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
TSHR P16473 2/20 0.50
L3MBTL1 Q9Y468 3/20 0.47
HTT P42858 1/20 0.47
PIN1 Q13526 1/20 0.47
ALDH1A1 P00352 4/20 0.47
MAPT P10636 3/20 0.46
RAB9A P51151 2/20 0.45
HPGD P15428 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.45
GLA P06280 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
HIF1A Q16665 1/20 0.44
MMP8 P22894 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6932566 1.00 KMT2A (0.73) KMT2ANPC1MEN1POLBNPSR1
SCHEMBL5100197 1.00 KMT2A (0.73) KMT2ANPC1MEN1POLBNPSR1
SCHEMBL5106479 0.86 KMT2A (0.54) KMT2ANPC1MEN1POLBL3MBTL1
SCHEMBL6014923 0.84 KMT2A (0.75) KMT2ANPC1MEN1POLBNPSR1
SCHEMBL29110220 0.83 KMT2A (0.55) KMT2ANPC1MEN1POLBTSHR
SCHEMBL27006319 0.83 L3MBTL1 (0.52) KMT2ANPC1MEN1POLBTSHR
SCHEMBL27130183 0.83 L3MBTL1 (0.52) KMT2ANPC1MEN1POLBTSHR
SCHEMBL5097060 0.83 L3MBTL1 (0.52) KMT2ANPC1MEN1POLBTSHR
SCHEMBL10830586 0.83 KMT2A (0.73) KMT2ANPC1MEN1POLBNPSR1
SCHEMBL2882513 0.82 HDAC3 (0.56) KMT2ANPC1MEN1L3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1070042-A2 PROCESS FOR THE PREPARATION OF HPB ESTERS Ciba SC Holding AG (CH) 2001-01-24 EP claimed
WO-1999050223-A2 PROCESS FOR THE PREPARATION OF HPB ESTERS CIBA SPECIALTY CHEMICALS HOLDING, INC. (CH) 1999-10-07 WO claimed
EP-4313986-A1 PROCESSES FOR MAKING BICYCLIC KETONE COMPOUNDS Genentech, Inc. (US) 2024-02-07 EP disclosed
US-20240034739-A1 PROCESSES FOR MAKING BICYCLIC KETONE COMPOUNDS GENENTECH, INC. (US) 2024-02-01 US disclosed
CN-117098762-A Process for preparing bicyclic ketone compounds 基因泰克公司 2023-11-21 CN disclosed
WO-2022212809-A1 PROCESSES FOR MAKING BICYCLIC KETONE COMPOUNDS GENENTECH, INC. (US) 2022-10-06 WO disclosed
CN-103898072-B A kind of Ketoreductase mutant and application thereof HANGZHOU NORMAL UNIVERSITY (CN) 2016-03-16 CN disclosed
CN-103898072-A Ketoreductase mutant and application thereof UNIV HANGZHOU NORMAL 2014-07-02 CN disclosed
US-6417389-B1 ENANTIOSELECTIVE HYDROGENATION USING PALLADIUM CATALYST AND CINCHONA ALKALOID CHIRAL MODIFIER CIBA SPECIALTY CHEMICALS CORPORATION 2002-07-09 US disclosed
EP-1070042-A2 PROCESS FOR THE PREPARATION OF HPB ESTERS Ciba SC Holding AG (CH) 2001-01-24 EP disclosed
WO-1999050223-A2 PROCESS FOR THE PREPARATION OF HPB ESTERS CIBA SPECIALTY CHEMICALS HOLDING, INC. (CH) 1999-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240034739-A1 PROCESSES FOR MAKING BICYCLIC KETONE COMPOUNDS HSD17B7, BCKDK, CYP11B1 KMT2A 1607/4885NPC1 331/4885MEN1 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.